When was Eigen founded?

Eigen was founded in 1973 and raised its 1st funding round 37 years after it was founded.

Where is Eigen located?

Eigen is headquartered in Grass Valley, United States.

How many employees does Eigen have?

As of Mar 31, 2026, the latest employee count at Eigen is 1158.

Is Eigen a funded company?

Eigen is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Oct 2010.

When was the latest funding round of Eigen?

Eigen's latest funding was a $***** Grant (prize money) round on May 01, 2018, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.83B in funding in 2026 to date.

Where does Eigen rank among its competitors?

Eigen ranks 8th amongst 36 active competitors, of which 12 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Nanostics, which secured an undisclosed amount in Apr, 2024.

Who are the top competitors of Eigen?

Eigen's top competitors include Artera, MDxHealth and Opko Health. Among them, Nanostics secured the most recent funding round in April, 2024.

Eigen - 2026 Company Profile, Funding & Competitors

Company Details

Developer of centralized lab-based imaging tools. The company's product Artemis converts the conventional 2D monochromatic ultrasound image to an enhanced 3D color image that helps urologists as a prostate biopsy guidance tool. Also, offers ProFuse which is a multi-modality image fusion software that has created a synergy between urology and radiology labs.

Website: eigen.com
Social
Email ID: *****@eigen.com

Key Metrics

Founded Year

1973

Location

Grass Valley, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), May 01, 2018, $*****

Investors

NIH & 1 more

Ranked

8^th among 36 active competitors

Employee Count

1,158 as on Mar 31, 2026

Similar Companies

Artera & 48 more

View Eigen's full profile

Eigen has raised funding over 3 rounds. Its first funding round was on Oct 2010. Its latest funding round was a Grant (prize money) round on May 01, 2018 for $*****. 1 investor participated in its latest round. Eigen has 2 institutional investors.

Here is the list of recent funding rounds of Eigen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 01, 2018	3551074	Grant (prize money)	7491725	8495577	6942437	8360656
Jan 2011	8204335	Grant (prize money)	1682418	9032727	5913797	NIH
Oct 2010	8027789	Grant (prize money)	8784846	6273561	4455105	NIH

Access funding benchmarks and valuations. Sign up today!

View details of Eigen's funding rounds and investors

Eigen's employee count trend

Eigen has 1,158 employees as of Mar 26. Here is Eigen's employee count trend over the years:

Uncover Eigen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eigen include Artera, MDxHealth and Opko Health. Here is the list of Top 10 competitors of Eigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Walden Catalyst, Coatue & 23 others	68/100
2nd	MDxHealth 2003, Irvine (United States), Public	Provider of epigenetic tests for personalized cancer assessment and treatment	-	Eiffel Investment Group, Orbimed & 12 others	60/100
3rd	Opko Health 1991, Miami (United States), Public	Provider of molecular diagnostic products	-	Oracle, Gates & 1 others	58/100
4th	ProteoMediX 2010, Schlieren (Switzerland), Acquired	Developer of next-generation blood test for prostate cancer	$17.6M	Altos Ventures Management, Venture Kick & 3 others	54/100
5th	A3P Biomedical 2020, Stockholm (Sweden), Seed	Developer of a blood test for early aggressive prostate cancer detection	-	Stena Sessan, Flerie & 3 others	46/100
6th	GenomeDx Biosciences 2008, San Diego (United States), Series C	Genomic tests for urologic cancers	$69.7M	Merck Global Health Innovation Fund, Calibrium ... & 6 others	46/100
7th	Immunis.AI 2012, Royal Oak (United States), Series C	Provider of platform for the detection of cancer	$40M	Savitr Capital	43/100
8th	Eigen 1973, Grass Valley (United States), Funding Raised	Developer of centralised lab based imaging tools	-	NIH, HHS	41/100
9th	Minomic 2000, Sydney (Australia), Series A	Non-invasive blood tests for cancer	$8.13M	ARC, M.H. Carnegie & Co & 1 others	41/100
10th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-	indyRIOT	40/100